Latest News
Contents
Zuellig Pharma and Institut AllergoSan sign 10-year regional partnership to bring leading probiotic brand OMNi-BiOTiC® to key markets in Asia
SINGAPORE, 19 July 2024
Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has signed a 10-year commercialisation partnership with Austria-based Institut AllergoSan, a research and development company that specialises in products made from natural substances such as probiotic bacteria, plant extracts and minerals.
Under this partnership, Zuellig Pharma will provide a wide spectrum of commercialisation support, including product registration, sales and marketing, and warehousing and distribution services to bring OMNi-BiOTiC®, one of Institut AllergoSan’s leading probiotic brands, to key markets in Asia.
“Our consumer healthcare segment will be one of the key growth drivers in our business over the coming years and this partnership represents a significant step forward in our commitment to delivering innovative and accessible healthcare solutions to patients in Asia. With a fast-growing probiotics market in Asia, the comprehensive and tailored solutions offered through our commercialisation division, ZP Therapeutics, will help our partners expand their footprint to meet greater consumer demand for gut health products in this region. Together with Institut AllergoSan, we will leverage our combined expertise to enhance the well-being of consumers and drive forward our mission of making healthcare more accessible,” said John Graham, Group CEO, Zuellig Pharma.
“We are dedicated to supporting consumers’ pursuit of a healthier, more vital self and offer medically relevant probiotic supplements that target specific health needs and deliver clinically backed results. OMNi-BiOTiC® is the top selling probiotic brand in all German-speaking markets in Europe such as Austria, Germany and Switzerland1 and we look forward to working closely with Zuellig Pharma to bring these innovative products to everybody in Asia who wants to promote an active, healthy life,” adds Anita Frauwallner, founder and CEO of Institut AllergoSan.
Zuellig Pharma plans to launch OMNi-BiOTiC® in Indonesia, the Philippines and Taiwan in 2025, followed by other key markets thereafter.
1 IQVIA OTC Global Insights 2023, 03F1/A7F, IQVIA OTC Audits / Public Price in EUR.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community.
For more information, visit: https://www.zuelligpharma.com/
A heart for bees: Institut AllergoSan creates flower meadow in the centre of the Styrian capital
Graz, May 2024
With the construction of a 10,000 m2 flower meadow, Institut AllergoSan is creating a new, urgently needed habitat for wild bees and other beneficial insects in the centre of Graz. As an important partner of the “BioBienenApfel” project and the resulting “BeeWild” initiative, the Styrian family business has been working intensively for several years to protect bees and preserve biodiversity.
Bees are of crucial importance for our ecosystem and biodiversity: in the EU, more than 80 % of crops and wild plants depend on pollination by bees. If there are fewer bees, plant diversity is also reduced, which can have far-reaching consequences – from yield losses in agriculture to the extinction of entire plant species, including fruits such as tomatoes or apples. This makes the decline in the bee population that has been observed worldwide in recent years all the more worrying. The causes are manifold: insecticides, monocultures, air pollution, climate change, but above all the loss of their habitat is causing the bees problems. Where are there still meadows where bees and other beneficial insects can live and nest?
New habitat for bees
Just such a meadow will soon blossom in the centre of the Styrian capital, in Graz-Puntigam. This is because Institut AllergoSan is based there – led by founder and director Anita Frauwallner – has set itself the task of creating a new habitat for bees and thus making a valuable contribution to preserving our environment and biodiversity. “Unfortunately, the number of wild bees and other beneficial insects has been steadily declining for years. It is therefore a matter close to my heart to protect these animals, which are so important for us and the environment, and to create a new habitat and refuge for them in the centre of the Styrian capital. In this way, we at Institut AllergoSan can contribute to passing on a thriving world to the next generation,” says Frauwallner, explaining her intensive commitment. A flower meadow is now growing on an area of 10,000 m2 (1 hectare) on the company premises in the centre of Graz, which will serve as an important habitat and nesting place for bees and numerous other beneficial insects.
For several years now, Institut AllergoSan has been a partner of the “BioBienenApfel” project and the resulting “BeeWild” initiative, which are actively working to create new habitats for beneficial insects and thus preserve biodiversity. For example, the Institut AllergoSan, known primarily for the high-quality, indication-specific probiotics of its OMNi-BiOTiC® brand, has already enabled the creation of 90,000 m2 of flower meadows for bees. Anita Frauwallner has always been committed to the environment and the careful use of natural resources, not least because the company works exclusively with substances provided by nature. For this reason, the institute will continue to work to protect the environment in a variety of ways. From its own electricity from renewable energy sources and the use of recycled materials for product packaging to a flowering retreat for bees on the company premises in the centre of the city.
Institut AllergoSan conquers global rankings
Graz, May 2023
It was a true pioneering spirit that drove Anita Frauwallner to embark on a largely unknown and risky path more than 30 years ago. Her focus on microbiome research and the development of innovative, high-quality probiotics led to the founding of Institut AllergoSan, and the creation of the probiotics brand OMNi-BiOTiC®, which is now number 1 in German-speaking countries as well as others.
The success of OMNi-BiOTiC® is continuing to spread around the globe, as the latest figures show[1] – in 2021, the brand was the 6th largest probiotics brand in the world, however, as of this year, OMNi-BiOTiC® is ranked 3rd globally!
“Thirty years ago, it was only important to me to help people to be able to live healthily and without restrictions with OMNi-BiOTiC®, however, I never considered that this would become a global brand,” says Anita Frauwallner, founder and director of Institut AllergoSan. “The success is not only shown by our outstanding clinical evidence but also by the noticeable difference within a few days of using our products, these are the reasons why OMNi-BiOTiC® products inspire so many people worldwide,” adds her son Bernd Assinger, Managing Director of Institut AllergoSan.
People in over 40 countries now benefit from using OMNi-BiOTiC® products. “It is therefore not surprising that OMNi-BiOTiC® is already considered a benchmark in the field of probiotics by experts and that the interest of potential new partners around the globe continues to grow,” comments Christian Gsöll, Director of Business Development at Institut AllergoSan, who is looking forward to further opportunities for expansion in the future.
Today, the OMNi-BiOTiC® range comprises sixteen probiotics specifically formulated for different indications. These contain synergistic strains of bacteria carefully selected for their abilities to colonise the human gut. To massively increase the activity of these intestinal inhabitants, they are embedded in a matrix of enzymes and key substances. Institut AllergoSan is a recognised centre of excellence for microbiome research and is known worldwide for innovative and highly effective products that have won numerous international awards, including top rankings in the US, such as the NutraIngredients Award “Probiotic of the Year” [2].
More than 100 research papers have been published on OMNi-BiOTiC®, 48 studies are currently ongoing and the scientific track record in high-ranking peer-reviewed journals is outstanding. This ensures the sustained success of the OMNi-BiOTiC® brand through new developments that will continue to emerge in new medical fields in the years to come. Impressive study results combined with excellent training concepts, as well as a proven international marketing toolkit, also give new distributors the chance to quickly reach top rankings in their probiotic OTC market.
“30 years ago, we set out to seek new possibilities in the field of preventive and natural medicine, which only a few specialists believed in at the time. 30 years later, we have now been able to help millions of people who put their trust in OMNi-BiOTiC® to noticeably improve their quality of life. We would like to continue on this path together with our committed team of employees, as we believe that it is possible, even from the small country of Austria, to achieve outstanding results at an international level when we combine the right ideas with our dedication and enthusiasm,” sums up Anita Frauwallner, CEO of Institut AllergoSan.
Sources:
[1] IQVIA Global OTC Insights – Local Currency Eur based on Public Price, Calender Year 2022 03F1 Probiotics Digest Health and 03D5 Antidiarr Micro-Organisms, IQVIA OTC audits
Hermes Business Award Winner!
Frauwallner sees the award not only as an award for work done: “Every award is at the same time our incentive – because every person deserves the best possible quality of life and health, and that is what my team and I work for with full commitment.
Sources:
1) https://hermes-wirtschafts-forum.at/hermes-wirtschafts-preis/wirtschafts-gala/
2) https://kurier.at/wirtschaft/das-sind-die-hermes-wirtschaftspreistraeger-2022/402207645
3) IQVIA / sell-out by value as of end December 2021
4) IQVIA Global OTC Insights – Local Currency Eur based on Public Price, Calender Year 2021 03F1 Probiotics Digest Health and 03D5 Antidiarr Micro-Organisms, IQVIA OTC audits
